Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Safety and efficacy of cilostazol in the management of intermittent claudication Chi YW; Lavie CJ; Milani RV; White CJVasc Health Risk Manag 2008[]; 4 (6): 1197-203Peripheral arterial disease (PAD) is a major health problem affecting millions of patients worldwide. Many will suffer from intermittent claudication (IC), which leads to marked impairment of quality of life (QoL). Besides surgical and endovascular interventions to improve limb-specific outcomes, pharmacotherapy is an effective tool in the treatment of IC. Cilostazol, a Federal Drug Administration-approved medication for the treatment of IC, has demonstrated consistent efficacy in improving exercise capacity and overall health-related QoL. This manuscript will review the pharmacokinetics, safety, and efficacy of cilostazol in the treatment of patients with IC as well as compare this agent with other proven non-invasive therapies for PAD.|Cardiovascular Agents/adverse effects/pharmacokinetics/*therapeutic use[MESH]|Cilostazol[MESH]|Exercise Tolerance/drug effects[MESH]|Humans[MESH]|Intermittent Claudication/*drug therapy/etiology/physiopathology[MESH]|Peripheral Vascular Diseases/complications/*drug therapy/physiopathology[MESH]|Quality of Life[MESH]|Tetrazoles/adverse effects/pharmacokinetics/*therapeutic use[MESH]|Treatment Outcome[MESH] |
